The strong revenue growth, substantial cash position, and positive clinical trial progress for VYD2311 create a favorable outlook. Traders should monitor the mid-2026 top-line data readout from the DECLARATION trial as a key catalyst, which could significantly impact the stock if results are positive.
Price Chart
Executive Summary
Invivyd reported strong financial and clinical progress, with Q4 2025 PEMGARDA net product revenue of $17.2 million (25% YoY growth) and a year-end cash position of $226.7 million after raising over $200 million in 2H 2025. The company's pivotal DECLARATION Phase 3 trial for its COVID-19 antibody VYD2311 is fully enrolled with top-line data expected mid-2026, and the FDA granted Fast Track designation for the candidate.
Key Financial Metrics
Key Facts
- Achieved Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
- 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
- Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026
- Fast Track designation for VYD2311 granted by FDA in December 2025
- DECLARATION trial on track with full enrollment achieved
- Distinguished scientist and physician Michael Mina, M.D., Ph.D., appointed Chief Medical Officer
Financial Impact
Q4 2025 revenue of $17.2 million (25% YoY growth) and full-year 2025 revenue of $53.4 million (111% YoY growth)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| PEMGARDA | $53.4M | +110.5% |
Risk Factors
- Clinical trial results may not meet expectations
- Regulatory approval is not guaranteed even with Fast Track designation
- Future revenue depends on successful commercialization of pipeline products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092528 |
| Document: d118119d8k.htm | 0001193125-26-092528 |
| Document: d118119dex992.htm | 0001193125-26-092528 |
| Document: 0001193125-26-092528-index-headers.html | 0001193125-26-092528 |
| Document: 0001193125-26-092528-index.html | 0001193125-26-092528 |
| Document: 0001193125-26-092528.txt | 0001193125-26-092528 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access